Compare ADMA Biologics Inc (ADMA) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Workday Inc — how do they compare? ADMA Biologics Inc trades at $9.91 (market cap $2.22B), while Workday Inc trades at $174.2 (market cap $44.77B). The key difference: Workday Inc is far larger — about 20.2× ADMA Biologics Inc's market cap, and Workday Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | WDAY | |
|---|---|---|
Market Cap | $2.22B | $44.77B |
Sector | Health | Technology |
52-Week High | $20.38 | $247.69 |
52-Week Low | $7.60 | $112.55 |
Enterprise Value | $2.29B | $44.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Workday (WDAY) trades at $184.19, up 2.53% with strong technical momentum and consecutive earnings beats. The stock shows bullish moving average signals despite overbought RSI readings. Revenue growth accelerated to $8.45 billion in 2025 with improving net margins of 6.22%, while analyst consensus remains positive with 55.6% buy ratings. Recent partnerships and AI product launches demonstrate continued innovation in enterprise software.
Outlook remains constructive given consistent earnings outperformance and AI-driven growth initiatives, though elevated valuation multiples and institutional selling present near-term headwinds. Key risks include competitive pressures and execution challenges in enterprise software market transitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
